To assess the prevalence of obstructive sleep apnoea (OSA) in men presenting with erectile dysfunction (ED) at a single centre.
Introduction
Obstructive sleep apnoea (OSA) is defined as repetitive upper airway occlusion resulting in snoring, episodes of hypoxia, disturbed sleep, and daytime somnolence [1] . It is estimated that the prevalence is up to 4% of men in the UK, with 1% having severe OSA [2, 3] . The risk factors for OSA include increasing age, obesity, and being male [1] [2] [3] [4] . OSA often coexists with hypertension and significant cardiovascular diseases, such as arrhythmias, heart failure, and coronary atherosclerosis [4, 5] . It has been postulated that OSA may be an important factor, not only in initiating the development of cardiovascular disease, but also in the acceleration of disease progression [4] . These factors all indicate that OSA is an extremely important and serious health condition, which may benefit from early identification and treatment [3] .
Erectile dysfunction (ED) shares similar comorbidities with OSA [6, 7] . The association between sleep disordered breathing and sexual dysfunction was first described by Guilleminault et al. [8] in 1981, when they reported a 48% ED rate in men with severe OSA. It has been estimated that 10-69% of men with OSA may also have ED [1, 9, 10] . However, the evidence for the association remains inconclusive with some studies suggesting no association once adjustments have been made for co-founders or an association only being present with severe OSA [3, 11] . The exact pathogenesis linking OSA and ED remains unclear but is likely to be multifactorial [1, 3, 7] . The factors implicated include increased sympathetic tone, endothelial dysfunction, hypoxia, and a reduction in nitric oxide (NO) formation [1, 3, 4] .
The link between ED and future cardiovascular disease events is now well established and is today a routine part of the ED assessment [12] . There is growing evidence that the same strategy should be applied to sleep apnoea [9] . Most of the published studies have been performed to determine the rate of ED in a population of men suspected of having sleep apnoea or referred for sleep studies.
The 'gold standard' for diagnosing sleep disorders is with polysomnography (PSG) [13] [14] [15] . However, this is costly, labour intensive, time consuming, and requires specialist clinicians. It is therefore necessary for non-specialist clinicians to have simple reliable tools that allow them to identify patients who are at high risk of having moderate-to-severe OSA and refer them onwards for specialist management [14] . There are several questionnaires that have been validated for these purposes [13] [14] [15] .
The aim of the present study was to assess the prevalence of sleep disorders and possible OSA according to questionnaire criteria in men presenting with ED at a single centre using two sleep disorder questionnaires.
Patients and Methods
Between February and September 2016, all new patients referred to our specialist andrology clinic with ED were included in this prospective non-randomised study. All men were required to complete three questionnaires: The International Index of Erectile Function (IIEF), the Obstructive Sleep Apnoea Screening questionnaire, and the Insomnia Severity Index (ISI) (Appendices S1-S3). The Obstructive Sleep Apnoea Screening questionnaire included the validated Epworth questionnaire.
All patients had their height and weight recorded for body mass index (BMI) calculation and were then subsequently reviewed by an andrologist, with their ED managed in accordance with usual practice and guidelines. A score of ≥3 on the Obstructive Sleep Apnoea Screening questionnaire suggested OSA and those patients were referred for specialist management and consideration for sleep studies. Men were excluded if the questionnaires were incomplete.
Questionnaires

The IIEF
The IIEF is a validated questionnaire used to assess the various domains of sexual function (erectile function, intercourse satisfaction, orgasm, desire, and overall satisfaction) over the previous 4 weeks [16] . The erectile function domain scores (IIEF-EF) determine ED severity and are classified as:
• 
Obstructive Sleep Apnoea Screening questionnaire
The Obstructive Sleep Apnoea Screening questionnaire combines two validated questionnaires [17] (Appendices S1 and S2): 'Epworth' and 'STOP BANG' (STOP: Snoring, Tiredness, Observed apnoea, high blood Pressure; BANG: BMI, Age, Neck circumference, Gender) [14] .
A score of ≥3 has a sensitivity of 92.9% in identifying moderate-to-severe OSA [14] . Mild OSA is unlikely to be clinically significant. The questionnaire uses four subjective (STOP: snoring, tiredness, observed apnoea, high blood pressure) and four demographic (BANG: BMI, age, neck circumference, gender) items [14] .
The tiredness component of the Obstructive Sleep Apnoea Screening questionnaire is measured by the Epworth sleepiness scale (Appendix S2). It is a validated eight-item questionnaire that rates the likelihood of falling asleep in eight specific common daily situations [15, 18] . The risk is scored 0-3, where zero is no chance and 3 is a high chance. The Epworth score correlates significantly with severity of OSA in patients undergoing PSG [15, 18] . Patients with scores of >10 are very likely to have a sleep disorder, although the exact type may be unclear [15, 18] .
The ISI
The ISI rates the subject's perception of their insomnia, its possible consequences, and any associated distress or concerns [13] (Appendix S3). It is a validated questionnaire with seven items. Each item is scored 0-4, with a total possible score of 28 [13] . A higher score is more likely to be associated with severe insomnia [13] . Insomnia is classified as:
• Normal: score 0-7 • Subthreshold: score [8] [9] [10] [11] [12] [13] [14] • Clinical insomnia (moderate): score [15] [16] [17] [18] [19] [20] [21] • Clinical insomnia (severe): score 22-28 [13] .
Statistical Analysis
Descriptive statistics of all variables was performed. The mean difference among all variables was determined using independent samples t-test between patients with an OSA 856 © 2017 The Authors BJU International © 2017 BJU International score of <3 (non-OSA group) and an OSA score of ≥3 (OSA group). Also, linear regression was used to determine whether there was any correlation between OSA and IIEF-EF domain scores.
Results
Complete data were available for 129 men, with a mean (range) age of 54.7 (20-76) years. Table 1 shows the baseline demographics of the study population.
All the IIEF and Obstructive Sleep Apnoea Screening questionnaires were completed for inclusion in the final analysis of this study. However, the ISI questionnaire was completed by 78% of the men included in the final analysis.
In all, 71 men (55%) scored ≥3 on the Obstructive Sleep Apnoea Screening questionnaire and were therefore referred for specialist management. This group (OSA group) was significantly older (61.4 vs 46.5 years; P < 0.001), with a higher BMI (29.4 vs 26.7 kg/m 2 ; P < 0.001), and were more likely to have had pelvic surgery (58% vs 38%; Table 1 ). They were also more likely to have risk factors for ED, such as a present or previous history of smoking (45% vs 22%), diabetes mellitus (25% vs 5%), hypertension (54% vs 12%), ischaemic heart disease (15% vs 9%), and a history of cerebrovascular accident (1% vs 0%) ( Table 1) .
Testosterone results were available in 61 men, with a mean of 15 nmol/L [15.5 nmol/L in the non-OSA group (OSA score of <3) vs 14.5 nmol/L in the OSA group). Six men (four in the OSA group) had low testosterone levels. Two men had already been started on testosterone replacement therapy, one had active prostate cancer, and three were lost to follow-up.
Overall, 75% of the whole group had severe ED, with a mean IIEF-ED domain score of 7.5. Men in the OSA group had significantly lower IIEF-ED domain scores (6.2 vs 9.1; P = 0.018) compared with men with in the non-OSA group. In addition, 82% (n = 58) of men in the OSA group had severe ED compared with 67% (n = 39) in men in the non-OSA group. There was a significant reduction in all domain scores, except overall satisfaction, for men within the OSA group compared with the non-OSA group (Table 2 ; Figs 1 and 2) .
At initial assessment, 78% of the whole group had already tried ED treatments (79% vs 76%, OSA vs non-OSA respectively). In the OSA group, 77% had tried phosphodiesterase type 5 inhibitors (PDE5-i) vs 72% in the non-OSA group. However, 58% in the OSA group had tried second-line ED treatments vs 38% in the non-OSA group (Table 3) .
After initial clinic review, men in the OSA and non-OSA groups respectively were most frequently managed with PDE5-i (28% vs 33%), second-line therapy (32% vs 22%) or added to the waiting list for the insertion of a penile prosthesis (24% vs 14%) ( Table 4) .
At the last follow-up, the most frequent management for men in the OSA and non-OSA groups respectively were PDE5-i (17% vs 14%), second-line therapy (39% vs 34%) and penile prosthesis (27% vs 14%) ( Table 5 ).
In all, 16 men had undergone insertion of a penile prosthesis with the rest still pending. This included 11 men in the OSA group and five in the non-OSA group. The mean length of stay after prosthesis insertion was 1.4 days and 1.2 days in the OSA group and non-OSA group, respectively. The mean ISI score was higher in the OSA group (7.9 vs 5.5; P = 0.061). Subthreshold insomnia was present in 31% (n = 17) in the OSA group vs 24% (n = 11) in the non-OSA group. Clinical insomnia was present in 15% (n = 8) in the OSA group vs 9% (n = 4) in the non-OSA group (Fig. 3) .
The mean Epworth score was significantly higher in the OSA group (6.5 vs 4.3; P = 0.004), and 24% of the men in the IHD, ischaemic heart disease; CVA, cerebrovascular accident; *P < 0.001 OSA group vs non-OSA group.
© 2017 The Authors BJU International © 2017 BJU International 857 OSA group (vs 5% in the non-OSA group) had an Epworth score of >10 (Fig. 4) .
Discussion
The present study confirmed a high prevalence of men with ED who are at risk of undiagnosed sleep apnoea, with 55% of ED patients referred to our centre being diagnosed with OSA, based on a score of ≥3 on the Obstructive Sleep Apnoea Screening questionnaire, and who were referred to specialist care for management of this condition. This was a high risk population, with 79% having already tried at least one first-line medical treatment for ED. In addition, at least one risk factor for ED was present in most of the group. In all, 82% of the whole group presented with severe ED, as categorised by their IIEF-ED score. As ED and OSA share risk factors, the presence of ED should raise the suspicion that the patient may also have an undiagnosed sleep disorder. It is estimated that by 2025, ED will affect 322 million men [19] . We can expect that the prevalence of sleep disorders may also rise in parallel with these numbers. As Urologists, we may be in a unique position to identify and refer men at risk for identification and treatment of sleep disorders.
Men in the OSA group (OSA score of ≥3) in our present study were twice as likely to be referred for the insertion of a penile prosthesis, despite having similar rates of treatment with first-and second-line management as the non-OSA group (OSA score of <3). This may suggest that they are less likely to respond to medical treatment. We would suggest that perhaps men with OSA scores of ≥3 should be referred for sleep studies and treated as appropriate before proceeding to the insertion of a penile prosthesis. This is similar to current management of diabetic men with ED, where their diabetic control is maximised before labelling them as 'PDE5-i failures'. This will require further research to determine the efficacy of this approach.
The men in the OSA group were more likely to have subthreshold insomnia and clinical insomnia compared to the non-OSA group. The OSA group also had a higher proportion of men with an Epworth score of >10, suggesting a type of sleep disorder. The identification of men with possible sleep disorders may allow us to identify a sub-group of men with difficult to treat sexual dysfunction who may require multi-modal management [20] [21] [22] [23] [24] [25] [26] [27] .
The mechanism for the link between OSA and ED is multifactorial and postulated to involve the following:
• Recurrent intermittent hypoxia;
• Changes in serum levels of sex hormones;
• Hypoxia induced neurological dysfunction;
• Reduction in the production of NO [7, 23, 28, 29] .
Disorders in sleep may result in hypoxia [7, 23, 28, 29] . Hypoxia in both animal and human models has been shown to result in an increase in sympathetic activity and oxidative stress [1, 9, 28, 29] . Both of these may subsequently result in vasoconstriction, dysfunction of vascular endothelial cells and the hypothalamo-pituitary-gonadal axis, and a reduction in NO [1, 9, 20] . Murine models have also shown a significant reduction in endothelial NO synthase in rats exposed to chronic hypoxia [28] . As the NO pathway requires oxygen as one of its substrates, hypoxia may also result in a reduction in the availability of tissue NO [21, 29] . Hypoxia may also result in nocturnal suppression of testosterone release [29] . Several authors have found lower levels of LH and testosterone in men with OSA [10, [30] [31] [32] [33] .
Many of these changes have a significant role in not only worsening ED but also in the development of serious cardiovascular disease. Several authors have suggested that sleep questions should be an important part of the sexual dysfunction assessment [3, 10, 29] . However, this has not yet appeared in national and international guidelines. We propose an easy method for identifying patients who are most at risk and require further assessment by a sleep specialist. The sleep questionnaires are simple to complete and may aid in the overall management of ED and improve cardiac health in general.
Limitations
Overall, we had a very high risk population, with most men referred after trialling other treatment modalities. This may have biased our present results more towards surgical intervention. In addition, we do not have the results from the sleep specialist.
In conclusion, we present real-life data in identifying men with OSA and sleep disorders in the ED population in a tertiary andrology department. Our population were a highrisk group for ED and sleep disorders, with 55% of the whole group diagnosed with OSA and referred for specialist management. This is a group who may potentially have progressed to the more serious consequences of OSA. We think the identification of OSA should be as important as cardiovascular risk assessment of men with ED. We would recommend the use of the Obstructive Sleep Apnoea Screening questionnaire to identify men who require referral to a sleep specialist.
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